322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)
Publication
, Journal Article
Smith, MA; Maris, JM; Keir, ST; Friedman, HS; Lock, RB; Kolb, EA; Keshelava, N; Reynolds, CP; Morton, C; Houghton, PJ
Published in: European Journal of Cancer Supplements
November 2006
Duke Scholars
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
November 2006
Volume
4
Issue
12
Start / End Page
101 / 101
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Smith, M. A., Maris, J. M., Keir, S. T., Friedman, H. S., Lock, R. B., Kolb, E. A., … Houghton, P. J. (2006). 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements, 4(12), 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5
Smith, M. A., J. M. Maris, S. T. Keir, H. S. Friedman, R. B. Lock, E. A. Kolb, N. Keshelava, C. P. Reynolds, C. Morton, and P. J. Houghton. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5.
Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, et al. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. 2006 Nov;4(12):101–101.
Smith, M. A., et al. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements, vol. 4, no. 12, Elsevier BV, Nov. 2006, pp. 101–101. Crossref, doi:10.1016/s1359-6349(06)70327-5.
Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. Elsevier BV; 2006 Nov;4(12):101–101.
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
November 2006
Volume
4
Issue
12
Start / End Page
101 / 101
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis